Prophylactic Indomethacin in Infants Born Extremely Preterm: Risks and Benefits Revisited

J Pediatr. 2023 Sep:260:113568. doi: 10.1016/j.jpeds.2023.113568. Epub 2023 Jun 15.

Author

Ronald I Clyman¹

Affiliation

¹ Department of Pediatrics and Cardiovascular Research Institute, University of California San Francisco, San Francisco, California.

PMID: 37329978
DOI: 10.1016/j.jpeds.2023.113568

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Ductus Arteriosus, Patent*
Humans
Indomethacin* / therapeutic use
Infant
Infant, Extremely Premature
Infant, Newborn
Risk Assessment

Substances

Indomethacin
Anti-Inflammatory Agents, Non-Steroidal